FAS and cancer: As an inhibitor of FAS, orlistat has been reported to have anti-angiogenic activity, including regulating the production of total VEGFA in cancer cells, reducing the formation of capillary-like structures, and decreasing the number of metastatic cervical lymph nodes in BALB/c nude mice (15, 16, 42).